Key result
A predictive nomogram incorporating age, ECOG performance status, neutrophil count, serum albumin, and hemoglobin accurately estimated the risk of grade 3/4 neutropenia (overall incidence 45.2%).
Why the study?
To develop and validate a predictive model including serum vitamin concentration to estimate the risk of chemotherapy-induced grade 3/4 neutropenia in patients receiving their first cycle of chemotherapy for esophageal, gastric, or colorectal cancer.
Can a nomogram accurately predict the risk of chemotherapy-induced grade 3/4 neutropenia in patients with gastrointestinal malignancies?
Cohort (n=747)
No
Can a nomogram accurately predict the risk of chemotherapy-induced grade 3/4 neutropenia in patients with gastrointestinal malignancies?
A newly developed nomogram incorporating clinical and laboratory parameters can accurately predict the risk of grade 3/4 neutropenia in patients with gastrointestinal cancers receiving first-cycle chemotherapy.
May aid neutropenia risk stratification in GI cancer chemotherapy; leaves open prospective validation before adoption.
OBJECTIVES: Development and validation of a predictive model including serum vitamin concentration to estimate the risk of chemotherapy-induced grade 3/4 neutropenia in esophageal cancer, gastric cancer, or colorectal cancer patients who receive the first cycle of chemotherapy. METHODS: Data from 535 patients treated at the Affiliated Fuyang People's Hospital of Anhui Medical University from January 1, 2020, to March 2, 2022, were used to derive the predictive model. Least absolute shrinkage and selection operator regression analysis was performed to screen potential risk characteristics, and multivariate logistic regression was utilized to investigate efficient factors associated with chemotherapy-induced neutropenia. A nomogram was constructed using this logistic model. This nomogram was then tested on a temporal validation cohort containing 212 consecutive patients. RESULTS: In the cohort of all 747 eligible patients, grade 3/4 neutropenia incidence was 45.2%. Age, Eastern Cooperative Oncology Group-performance status, neutrophil count, serum albumin, and hemoglobin data were entered into the final model. The performance of the final predictive nomogram was assessed by the area under the receiver operating characteristic curve in both the development and validation datasets. The calibration curves indicated that the estimated risks were accurate. Decision curve analysis for the predictive model exhibited improved clinical practicality. CONCLUSION: In the present study, we established an accessible risk predictive model and identified valuable serum vitamin concentration parameters associated with chemotherapy-induced neutropenia. The predictive model may improve the grade 3/4 neutropenia risk prediction in patients with gastrointestinal malignancies who receive oxaliplatin- and fluoropyrimidine-based chemotherapy and help physicians make appropriate decisions for disease management.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2024) conducted a cohort in Esophageal, gastric, or colorectal cancer (n=747). Predictive nomogram (age, ECOG-PS, neutrophil count, serum albumin, hemoglobin) was evaluated on Grade 3/4 neutropenia. A predictive nomogram incorporating age, ECOG performance status, neutrophil count, serum albumin, and hemoglobin accurately estimated the risk of grade 3/4 neutropenia (overall incidence 45.2%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: